33620 Results

People

  1. Ladanyi
    Ladanyi
  2. Giralt
    Giralt
  3. Motzer
    Motzer
  4. Reuter
    Reuter
  5. Perales
    Perales
  6. Scher
    Scher
  7. Zelenetz
    Zelenetz
  8. Berger
    Berger
  9. Al-Ahmadie
    Al-Ahmadie
  10. O'Reilly
    O'Reilly

Groups

  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)
  7. Department of Pathology and Laboratory Medicine (5172)
  8. Surgery (4871)
  9. Sloan Kettering Institute Faculty (3826)
  10. Sloan Kettering Institute Postdocs (3612)
  1. "Meeting abstract"
Formats
  1. Meeting Abstract (33620)
Groups
  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)

More Groups

People
  1. Marc Ladanyi (641)
  2. Sergio Giralt (632)
  3. Robert Motzer (574)
  4. Victor Reuter (568)
  5. Miguel-Angel Perales (482)
  6. Howard Scher (463)

More People

Years
  1. 2025 (295)
  2. 2024 (1694)
  3. 2023 (1954)
  4. 2022 (2196)
  5. 2021 (1731)
  6. 2020 (1901)

More Years

Publications
  1. Journal of Clinical Oncology (6252)
  2. Blood (3939)
  3. Laboratory Investigation (1846)
  4. Cancer Research (1822)
  5. International Journal of Radiation Oncology, Biology, Physics (1643)
  6. Modern Pathology (1494)

More Publications

Publishers
  1. American Society of Clinical Oncology (6251)
  2. Elsevier Inc. (4694)
  3. American Society of Hematology (3939)
  4. American Association for Cancer Research (3045)
  5. Nature Publishing Group (2151)
  6. Oxford University Press (2096)

More Publishers

Results (33620)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A randomized phase III clinical trial of acupuncture for chemotherapy-induced peripheral neuropathy (CIPN) in cancer survivors
    Meeting Abstract

    Dooley, A.; Han, K.; Zhi, W. I.; Piulson, L.; Seluzicki, C.; Bao, T.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Long-term efficacy and safety of larotrectinib in a pooled analysis of patients with tropomyosin receptor kinase (TRK) fusion cancer
    Meeting Abstract

    Drilon, A. E.; Hong, D. S.; Van Tilburg, C. M.; Doz, F.; Tan, D. S. W.; Kummar, S.; Lin, J. J.; McDermott, R. S.; Zwaan, C. M.; Norenberg, R.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • A phase 2 study of the MDM2 inhibitor milademetan in patients with TP53-wild type and MDM2-amplified advanced or metastatic solid tumors (MANTRA-2)
    Meeting Abstract

    Dumbrava, E. E.; Hanna, G. J.; Cote, G. M.; Stinchcombe, T.; Johnson, M. L.; Chen, C.; Devarakonda, S.; Shah, N.; Xu, F.; Doebele, R. C.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • A phase 1/2 study of REGN5093-M114, a METxMET antibody-drug conjugate, in patients with mesenchymal epithelial transition factor (MET)-overexpressing NSCLC
    Meeting Abstract

    Drilon, A. E.; Awad, M. M.; Gadgeel, S. M.; Villaruz, L. C.; Sabari, J. K.; Perez, J.; Daly, C.; Patel, S.; Li, S.; Seebach, F. A.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Updated efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion lung cancer
    Meeting Abstract

    Drilon, A. E.; Lin, J. J.; Kummar, S.; Tan, D. S. W.; Patel, J. D.; Lassen, U. N.; Leyvraz, S.; Moreno, V.; Rosen, L. S.; Solomon, B. M.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • nab-Sirolimus for patients with advanced malignant PEComa with or without prior mTOR inhibitors: Biomarker results from AMPECT and an expanded access program
    Meeting Abstract

    Dickson, M. A.; Ravi, V.; Riedel, R. F.; Ganjoo, K. N.; Van Tine, B. A.; Chugh, R.; Cranmer, L. D.; Gordon, E. M.; Chen, J. L.; Murphy, M. C.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Treatment exposure-based risk-stratification for care of survivors of childhood cancer: A report from the Childhood Cancer Survivor Study
    Meeting Abstract

    Dinan, M. A.; Stratton, K.; Leisenring, W. M.; Yasui, Y.; Chow, E. J.; Moskowitz, C. S.; Yeh, J. M.; Noyd, D. H.; Armstrong, G. T.; Oeffinger, K. C.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • A phase 1 trial of D2C7-it in combination with an Fc-engineered anti-CD40 monoclonal antibody (2141-V11) administered intratumorally via convectionenhanced delivery for adult patients with recurrent malignant glioma (MG)
    Meeting Abstract

    Desjardins, A.; Chandramohan, V.; Landi, D. B.; Johnson, M. O.; Khasraw, M.; Peters, K. B.; Low, J.; Herndon, J. E.; Threatt, S.; Bullock, C. A.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Overcoming barriers to tumor genomic profiling through direct patient social media outreach
    Meeting Abstract

    Doe-Tetteh, S. A.; Camp, S. Y.; Crowdis, J.; Noronha, A. M.; Reales, D.; Alano, T.; Viale, A.; Donoghue, M.; Socci, N. D.; Berger, M. F.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Clinical characteristics and treatment outcomes in patients with histiocytic neoplasms harboring class 3 MAP2K1 mutations, including treatment with the ERK inhibitor ulixertinib
    Meeting Abstract

    Diamond, E. L.; Yabe, M.; Petrova-Drus, K.; Rosenblum, M.; Rotemberg, V.; Lacouture, M. E.; Rampal, R.; Francis, J.; Knoerzer, D.; Kreider, B.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save